World’s First! In Vivo CAR-T Successfully Treats Systemic Lupus Erythematosus: A Revolutionary Breakthrough in Immune Reprogramming
World’s First! In Vivo CAR-T Successfully Treats Systemic Lupus Erythematosus: A Revolutionary Breakthrough in Immune Reprogramming
In recent years, cellular immunotherapy has rapidly expanded from oncology into the field of autoimmune diseases. Among these advances, in vivo CAR-T has emerged as one of the most disruptive frontier technologies.
Particularly in systemic lupus erythematosus (SLE)—a chronic and difficult-to-treat autoimmune disease—in vivo CAR-T therapy is demonstrating the potential to “reset the immune system,” and is even considered capable of achieving functional cure. This breakthrough marks the official entry of immunotherapy into the era of in vivo engineering.
DengYueMed adheres to the principles of compliance, transparency, and efficiency, providing reliable solutions for global patients to access innovative therapies.
Systemic Lupus Erythematosus: Limitations of Conventional Treatments
Systemic lupus erythematosus is a complex autoimmune disease characterized by the immune system mistakenly attacking the body’s own tissues, leading to multi-organ damage. Current treatments mainly rely on:
● Glucocorticoids
● Immunosuppressants
● Biologics (such as anti-B cell therapies)
However, these approaches face several limitations:
● They cannot cure the disease, only control symptoms
● Long-term use leads to significant side effects
● High rates of disease relapse
Therefore, there is an urgent clinical need for therapies capable of fundamentally rebuilding the immune system, and CAR-T technology offers such a possibility.
What Is In Vivo CAR-T Therapy?
Traditional CAR-T therapy (ex vivo CAR-T) involves extracting T cells from patients, genetically engineering them outside the body, and reinfusing them—resulting in a complex and costly process.
In contrast, in vivo CAR-T represents a completely new paradigm:
👉 CAR-T cells are generated directly in the patient’s body
Its core principle involves using delivery systems such as lipid nanoparticles (LNPs) to transport CAR-encoding mRNA into T cells, enabling them to express CAR receptors in vivo and acquire the ability to recognize and eliminate target cells.
This approach significantly simplifies the treatment process and is regarded as a major upgrade to traditional CAR-T technology.
Mechanism of Action: How Does It “Reset” the Immune System?
In SLE, abnormal activation of B cells is a key driver of disease progression. In vivo CAR-T therapy primarily targets B-cell markers such as CD19 to achieve the following:
1️⃣ Precise Identification of Pathogenic B Cells
CAR structures specifically recognize CD19-positive B cells for accurate targeting.
2️⃣ Rapid Elimination of Abnormal Immune Cells
CAR-T cells release perforin and granzymes, inducing apoptosis in B cells.
3️⃣ Removal of Autoantibody Sources
Following B-cell depletion, autoantibody levels drop significantly.
4️⃣ Restoration of Immune Tolerance
As new B cells regenerate, the immune system gradually returns to a normal state.
👉 Essentially, this process resembles a “factory reset” of the immune system.
Clinical Breakthrough: Key Advances in In Vivo CAR-T for SLE
🔬 First-in-Human Study Results (2025)
In the latest studies, researchers successfully generated CAR-T cells inside patients using an mRNA-LNP delivery system, achieving remarkable outcomes:
● Approximately 60% of CD8+ T cells were converted into CAR-T cells
● Complete depletion of circulating B cells
● Significant reduction in SLE disease activity scores (up to 20 points)
● No severe neurotoxicity or major adverse events observed
This marks the first successful validation of in vivo CAR-T in human SLE patients.
📊 Supporting Evidence from Conventional CAR-T
Although in vivo CAR-T is still in early stages, prior studies of traditional CAR-T provide strong support:
● Approximately 81% of patients achieved low disease activity
● Some patients reached long-term drug-free remission
● In small studies, remission occurred within 3 months
These findings indicate:
👉 Eliminating B cells can fundamentally reverse the course of SLE
Comparison with Traditional CAR-T
| Dimension | Traditional CAR-T | In Vivo CAR-T |
|---|---|---|
| Manufacturing | Ex vivo engineering | In vivo generation |
| Treatment process | Complex | Simplified |
| Cost | High | Potentially lower |
| Accessibility | Limited | Broader |
| Development stage | Relatively mature | Early clinical |
👉 Clearly, in vivo CAR-T represents the next generation of CAR-T technology.
Future Directions
The development of in vivo CAR-T in SLE is likely to focus on:
● Multi-target CAR designs (e.g., CD19 + BCMA)
● Deep integration with mRNA technologies
● Personalized immune modulation strategies
● Combination therapies with biologics
In the future, its applications may expand to:
● Rheumatoid arthritis
● Multiple sclerosis
● Type 1 diabetes
👉 Evolving from a single-disease solution to a broad autoimmune platform
Conclusion: From Treatment to “Immune Reset”
In vivo CAR-T therapy is reshaping our understanding of autoimmune disease treatment—it is no longer about merely suppressing immunity, but about rebuilding it.
In systemic lupus erythematosus, this technology achieves deep immune remodeling by precisely eliminating pathogenic B cells, demonstrating the potential for near-functional cure.
Although still in early development, continuous advances in mRNA delivery and cellular engineering are expected to position in vivo CAR-T as a key pillar in the future treatment of autoimmune diseases. A new era of “programmable in vivo immunotherapy” is rapidly approaching.